Abstract: A dissolvable orally adhering tablet for sustained release is disclosed, the tablet comprising an active ingredient, wherein the tablet is a multilayer tablet comprising a first layer and a second layer, the first layer being a mucoadhesive layer comprising a natural gum mucoadhesive and the second layer comprising at least one sugar alcohol.

Abstract: A nicotine pouch composition is disclosed, the composition comprising nicotine, water-insoluble fibers, and a particulate inert filler, wherein the pouch composition comprises said inert filler in an amount of at least 5% by weight of the pouch composition, wherein the pouch composition further comprises at least 10% by weight of water. Also, a pouched product is disclosed.

Abstract: The present invention relates to an adhesive oral disc for sustained release of cannabinoids. The disc comprises one or more cannabinoids and being composed of at least a mucosal contacting layer having a mucosal contacting surface operable to be 5 fixed to the gingiva of a person in need of alleviation or treatment of a medical condition, where the mucosal contacting layer comprising one or more mucoadhesive polymers allowing the adhesive oral disc to adhere to the gingiva for an extended period of time. Further, the disc comprises a non-mucoadhesive module fused to the mucosal contacting layer, where the non-mucoadhesive module comprising a solid 10 tablet composition allowing the non-mucoadhesive module to dissolve within an extended period of time upon adhesion of the adhesive oral disc to the gingiva. The invention is particularly useful for alleviation or treatment of ulcers.

Abstract: The invention relates to a powder premixture for oral administration of cannabinoids, comprising a cannabinoid powder composition comprising one or more isolated cannabinoids in an amount of at least 2% by weight of the powder premixture; a lipid composition comprising one or more triglycerides in an amount of at least 1.0% by weight of the powder premixture; and a sweetener powder composition comprising one or more sweeteners, wherein the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:50 to 1:4.

Abstract: A nicotine pouched product is disclosed, the pouched product comprising a pouch composition and a saliva-permeable pouch enclosing said pouch composition, the pouch composition comprising nicotine and a pouch substrate, the pouch substrate comprising water-insoluble fiber, wherein said pouch composition comprises nicotine in an amount of at least 0.25% by weight of the pouch composition, and wherein the pouched product comprises said pouch composition in an amount of no more than 400 mg.

Abstract: A soft chew tablet based on proteins includes a core constituting a coherent uncooked mass including: one or more indigestible water soluble fibers in an amount of 10 to 45% by weight of the core, one or more powdered proteins in an amount of 10 to 60% by weight of the core, and one or more texturizers in an amount of 0.1 to 25% by weight of the core.

Abstract: A soft chew tablet includes a core constituting a coherent uncooked mass including: one or more indigestible water soluble fibers in an amount of 10 to 45% by weight of the core, one or more powdered sugar alcohols in an amount of 10 to 45% by weight of the core, one or more texturizers in an amount of 0.1 to 15% by weight of the core, and one or more active ingredients in an amount of 1 to 60% by weight of the core.

Abstract: Disclosed is an oral nicotine pouch composition comprising nicotine, water in an amount of at least 5% by weight of the pouch composition, alginate, inorganic divalent cations, and at least one pH regulating agent comprising inorganic phosphate. Also disclosed is an oral nicotine pouch composition comprising inorganic multivalent cations and a pouched product.

Abstract: An orally dissolvable or chewable tableted powder formulation is presented. The formulation includes one or more carrier systems including one or more liquid or solid self-emulsifying systems loaded with cannabinoids in an amount of at least 10% by weight of the tableted powder formulation. The one or more self-emulsifying systems includes: at least one or more surfactants, one or more lipids and one or more isolated or synthetic cannabinoids when self-emulsifying system is a liquid self-emulsifying system, and at least one or more surfactants, one or more waxes and one or more isolated or synthetic cannabinoids when self-emulsifying system is a solid self-emulsifying system. The formulation further includes one or more water-soluble agents in an amount of 20-80% by weight of the tableted powder formulation and one or more flavors. The one or more surfactants includes one or more surfactants having a chemical structure that includes a polyethylene glycol moiety.

Abstract: A capsule for peroral delivery of cannabinoids includes a cannabinoid formulation contained in a hard shell or soft shell of the capsule. The formulates include: one or more self-emulsifying drug delivery systems (SEDDS) including one or more surfactants having a chemical structure that includes a polyethylene glycol (PEG) moiety in an amount of at least 20% by weight of the one or more SEDDS; and one or more cannabinoids including one or more isolated or synthetic cannabinoids in an amount of at least 10% by weight of the formulation.

Abstract: A dosage form for delivery of cannabinoids includes a formulation including: one or more self-emulsifying drug delivery systems (SEDDS) including one or more surfactants having a chemical structure that includes a polyethylene glycol (PEG) moiety in an amount of at least 30% by weight of the one or more SEDDS; and one or more cannabinoids including one or more isolated or synthetic cannabinoids in an amount of at least 10% by weight of the formulation.

Abstract: A nicotine pouched product is disclosed, the pouched product comprising a pouch composition and a saliva-permeable pouch enclosing said pouch composition, the pouch composition comprising nicotine and a pouch substrate, the pouch substrate comprising water-insoluble fiber, wherein said pouch composition comprises nicotine in an amount of at least 0.25% by weight of the pouch composition, and wherein the pouched product comprises said pouch composition in an amount of no more than 400 mg.

Abstract: A flowpack for oral delivery of active ingredients comprises a population of particles and one or more active ingredients, the population of particles including at least two types of sugar alcohol particles, wherein at least one of said two types of sugar alcohol particles comprises granulated sugar alcohol particles.

Abstract: The invention relates to oral analgesic compositions for alleviation of perceived nicotine irritation through inhibition or blocking of nicotine activated receptors or ion channels in the gastrointestinal tract, including the oral cavity. The composition of the invention comprises one or more nicotine sources, one or more buffering agents, and at least two antagonists in an effective amount to inhibit or block nicotine agonist activation of Nicotinic Acetylcholine Receptors (nAChR) and/or Transient Receptor Potential (TRP) ion channels, the at least two antagonists being selected from the group consisting of a first antagonist comprising camphor or one or more compounds resembling camphor, a second antagonist comprising eucalyptol, and a third antagonist comprising (1R,2S,5R)—N-(4-Methoxyphenyl)-5-methyl-2-(1-methylethyl)cyclohexanecarboxamide (WS-12).

Abstract: An orally dissolvable or chewable tableted powder formulation is presented. The formulation includes one or more carrier systems including one or more liquid or solid self-emulsifying systems loaded with cannabinoids in an amount of at least 10% by weight of the tableted powder formulation. The one or more self-emulsifying systems includes: at least one or more surfactants, one or more lipids and one or more isolated or synthetic cannabinoids when self-emulsifying system is a liquid self-emulsifying system, and at least one or more surfactants, one or more waxes and one or more isolated or synthetic cannabinoids when self-emulsifying system is a solid self-emulsifying system. The formulation further includes one or more water-soluble agents in an amount of 20-80% by weight of the tableted powder formulation and one or more flavors. The one or more surfactants includes one or more surfactants having a chemical structure that includes a polyethylene glycol moiety.

Abstract: A crystalline cannabinoid powder includes cannabinoid crystal particles having a cannabinoid purity of at least 95% by weight and a Specific Surface Area (SSA) of at least 0.7 m2/g. A crystalline cannabinoid powder includes cannabinoid crystal particles having a degree of crystallinity of at least 90% and a Specific Surface Area (SSA) of at least 0.7 m2/g. These powders may be prepared by a dry-milling or wet-milling method, and alternatively by a re-crystallization method.

Abstract: The invention relates to an orally disintegrating nicotine tablet for nicotine craving relief comprising a pressed powder formulation, the tablet being designed to disintegrate within a period of less than 60 seconds upon oral administration, the powder formulation comprising an amount of nicotine and a pH regulating agent.

Abstract: A water-dissolvable compressed oral nicotine lozenge is disclosed, the oral nicotine lozenge comprising a first module and a second module, the first and the second modules being fused by compression, the first module being a lozenge module comprising at least one sugar alcohol and the second module being an FDT-module comprising at least one sugar alcohol and nicotine. Also, a method of manufacturing a water-dissolvable compressed oral nicotine lozenge is disclosed.

Abstract: The invention relates to an orally disintegrating nicotine tablet for nicotine craving relief comprising a pressed powder formulation, the tablet being designed to disintegrate within a period of less than 60 seconds upon oral administration, the powder formulation comprising an amount of nicotine and a pH regulating agent.

Abstract: A powder mixture for oral delivery of active ingredients includes a population of particles and one or more active ingredients, the population of particles including at least two types of sugar alcohol particles. At least one of the at least two types of sugar alcohol particles takes the form of i) non-directly compressible (non-DC) sugar alcohol particles or ii) directly compressible (DC) sugar alcohol particles that are not granulated sugar alcohol particles. At least one of the at least two types of sugar alcohol particles has a particle size with more than 50% of the particles being below 250 microns, and at least one of the at least two types of sugar alcohol particles is present in an amount of at least 20% by weight of the powder mixture.